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Background
Approach to autoimmune diseases remains a challenge,
not only by their clinical complexity but also because of
frequent refractoriness to conventional treatment. We
report 3 cases in which B cells depletion, with monoclo-
nal antibody anti-CD20, appears as a therapeutic option
to consider.
Case 1
17-year-old boy referred to the Autoimmune Diseases
Centre with symmetrical proximal muscle weakness,
weight loss, dysphagia, periungual lesions and erythema
of hands and eyelids with a year of evolution. Laboratory
tests showed elevated lactate dehydrogenase, creatine
kinase, transaminases and aldolase. Immunological/sero-
logical tests were negative. Capillaroscopy was compati-
ble with Juvenile Dermatomyositis. Electromyography
and muscle biopsy revealed nonspecific inflammatory
myopathy. Corticosteroids were used but there was pro-
gression of disease. Rituximab was introduced with sig-
nificant clinical improvement.
Case 2
11-year-old girl diagnosed with Mixed Connective Tis-
sue Disease for 1 year, with adverse reactions to corti-
costeroids. Completed 4 cycles of Rituximab with total
regression of skin lesions and CD19 depletion. Eight
months after, there was laboratory and clinical recur-
rence, with arthritis, vasculitis, weight loss, and elevation
of CD19. The second cycle of Rituximab was performed
uneventfully with clinical improvement and progressive
CD19 normalization.
Case 3
13-year-old girl diagnosed with Systemic Sclerosis with
blood vessel, gastrointestinal and muscle/joint involve-
ment. Despite the improvement of Raynaud’sp h e n o m -
enon with bosentan, she progressed to hip arthritis with
gait impairment and severe pain. Refractory to conven-
tional treatment, completed 4 cycles of Rituximab with
clinical improvement, hip arthritis complete recovery
and CD19 depletion.
Conclusion
Rituximab seems to be an effective alternative for severe
and refractory autoimmune diseases.
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